• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies
CONCLUSIONS: This systematic review supports findings from subgroup analyses of randomized controlled trials that, compared with warfarin, rivaroxaban is associated with generally neutral or positive effects on thrombosis and a mixed picture on bleeding outcomes in older adults with either NVAF or VTE treated in the United States.PMID:37584187 | DOI:10.1080/03007995.2023.2247988
Source: Current Medical Research and Opinion - August 16, 2023 Category: Research Authors: William L Baker Matthew S Roberts Youssef Bessada Kimberly S Caroti Veronica Ashton Brahim K Bookhart Craig I Coleman Source Type: research

Impact of atrial fibrillation and anticoagulation on the risk of death, thromboembolic disease and bleeding in patients with COVID-19: the ACO-VID Registry
CONCLUSIONS: Among patients hospitalized with COVID-19, patients with AF were older, had more comorbidities and had a higher risk of major bleeding. Age and elevated transaminases during hospitalization, but not AF nor anticoagulant treatment increased the risk of all-cause death.PMID:37189306 | DOI:10.1080/03007995.2023.2204009
Source: Current Medical Research and Opinion - May 16, 2023 Category: Research Authors: Juan Jos é Cerezo Manchado Teodoro Iturbe Hern ández Mar ía Del Carmen Martínez Pacheco Ignacio Gil Ortega Desir ée Campoy Tania Canals Pernas Laia Mart ínez Serra Katia Jessica Flores Aparco C ésar Andrés Velásquez Escandón Antonio Mart ínez F Source Type: research

Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19
CONCLUSION: NVAF patients with COVID-19 who discontinued apixaban had a higher risk of hospitalization and thrombotic events vs. those who continued apixaban, with no significant difference in bleeding-related hospitalization.PMID:36000258 | DOI:10.1080/03007995.2022.2112871
Source: Current Medical Research and Opinion - August 24, 2022 Category: Research Authors: Steven Deitelzweig Julia Zhu Jenny Jiang Xuemei Luo Allison Keshishian Mauricio Ferri Lisa Rosenblatt Patricia Schuler Cynthia Gutierrez Amol D Dhamane Source Type: research

Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research

Impact of geriatric syndromes on anticoagulation prescription in older adults with atrial fibrillation
CONCLUSIONS: Age and CKD were significantly associated with anticoagulation prescription in patients with AF. Further studies on the impact of geriatric syndromes on anticoagulation prescription and outcomes in older adults are needed with specific guidelines for patients with geriatric syndromes and AF.PMID:34714212 | DOI:10.1080/03007995.2021.2000717
Source: Current Medical Research and Opinion - October 29, 2021 Category: Research Authors: Li Feng Tan Rodney Soh Christopher Koo Wilson Goh Goy Shen Jiayi Lim Santhosh Seetharaman Reshma Merchant Source Type: research

The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review
CONCLUSIONS: Rates of nontreatment and undertreatment among NVAF patients remain high and are associated with preventable cardiovascular events and death. Strategies to increase rates of treatment may improve clinical outcomes.PMID:34632887 | DOI:10.1080/03007995.2021.1982684
Source: Current Medical Research and Opinion - October 11, 2021 Category: Research Authors: Matthew Sussman Geoffrey D Barnes Jennifer D Guo Charles Y Tao John A Gillespie Mauricio Ferri Nicholas Adair Matthew S Cato Ilnaz Shirkhorshidian Manuela Di Fusco Source Type: research

Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
CONCLUSIONS: These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population.PMID:33733969 | DOI:10.1080/03007995.2021.1901223
Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Jeffrey S Berger Fran çois Laliberté Akshay Kharat Dominique Lejeune Kenneth Todd Moore Young Jung Patrick Lefebvre Veronica Ashton Source Type: research

Pages: 1  2  3